美国甲状腺协会超声风险适应策略在良性甲状腺结节重复细胞学检查中的验证
该回顾性队列研究纳入1010个初始细胞学良性、随访中至少重复一次细针穿刺细胞学检查(FNAC)的甲状腺结节,中位随访3.8年。结果显示全队列漏诊癌率为1.0%,随超声风险分级升高而增加(极低/低危0.8%、中危1.2%、高危3.1%);2015年ATA超声风险分层系统排除无需第二次FNAC的阴性预测值为99.1%。在体积增大的结节中漏诊癌率随风险分级显著增加(低危0.4% vs 高危6.4%,p=0.005),而未增大结节中漏诊癌率很低且与超声特征无关(p=0.96)。
要点
- 全队列漏诊癌率为1.0%,极低/低危0.8%、中危1.2%、高危3.1%。
- ATA超声风险分层排除无需重复FNAC的阴性预测值为99.1%。
- 体积增大结节中漏诊癌率低危0.4% vs 高危6.4%(p=0.005);未增大结节中与超声特征无关(p=0.96)。
核心结论
- 结果证实ATA推荐在随访中筛选良性结节重复FNAC的准确性。
- 低危超声特征的良性甲状腺结节无论随访中是否增大,或可避免额外的细胞学评估。
- 高危超声特征良性结节常规重复FNAC的价值尚待明确,基于本研究结果,对随访中增大的结节似乎有指征重复FNAC。
研究设计与样本
- 回顾性队列研究,纳入1010个初始细胞学良性、随访中至少重复一次FNAC的甲状腺结节,中位随访3.8年(范围1.0-14.2年)。
主要发现
- 全队列漏诊癌率为1.0%,随超声风险分级升高:极低/低危0.8%、中危1.2%、高危3.1%。
- 2015年ATA超声风险分层系统筛选无需第二次FNAC的阴性预测值为99.1%。
- 体积增大的结节中漏诊癌率随风险分级显著增加:低危0.4% vs 高危6.4%(p=0.005)。
- 未增大的结节中漏诊癌率很低且与超声特征无关(p=0.96)。
关键数值与推荐
- 2015年ATA超声风险分层系统用于识别需行FNAC的甲状腺结节并规划细胞学良性结节的长期随访。
- 阴性预测值=99.1%对应2015年ATA超声风险分层系统筛选无需第二次FNAC的结节。
临床怎么用
- 作者认为,低危超声特征的良性甲状腺结节无论随访中是否增大,或可避免额外的细胞学评估。
- 作者认为,基于本研究结果,对随访中增大的结节似乎有指征重复FNAC。
- 作者指出,高危超声特征良性结节常规重复FNAC的价值尚待明确。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The 2015 American Thyroid Association (ATA) ultrasound (US) risk stratification system is used to identify thyroid nodules in which fine-needle aspiration cytology (FNAC) should be performed. In addition, this system is used to plan the long-term follow-up of patients with cytological benign thyroid nodules. The aim of our study was to evaluate the ATA US risk-adapted approach for repeating cytology in a large retrospective cohort of consecutive benign nodules with a second FNAC repeated after a median follow-up of 3.8 years (range 1.0-14.2 years). Methods: We retrospectively evaluated 1010 thyroid nodules, with an initial benign cytological diagnosis, that underwent at least one repeat FNAC during the follow-up. Results: The rate of missed cancer in the whole cohort of thyroid nodules was 1.0%, and it increased along by the US risk class (0.8% in very low/low-risk, 1.2% in intermediate-risk, and 3.1% in high-risk nodules). The 2015 ATA US risk stratification system showed a very high accuracy in selecting nodules that did not require a second FNAC (negative predictive value = 99.1%). In addition, the rate of missed cancer significantly increased along with the increase in the US risk class in nodules that showed an enlarged volume (0.4% in the low-risk class and 6.4% in the high-risk class, p = 0.005), while it was very low and not associated with the US features in the subgroup of thyroid nodules that did not grow during the follow-up (p = 0.96). Conclusions: Our results confirm the accuracy of the ATA recommendations in selecting benign nodules for FNAC repetition during the follow-up. An additional cytological evaluation maybe avoided in benign thyroid nodules with low-risk US features, regardless of the evidence of growth during the follow-up. While the utility of the routine repeat FNAC in all benign nodules with high-risk US features remains to be defined, based on our results, repetition of FNAC seems to be indicated in nodules with evidence of growth during the follow-up.
引用
- Maino F, Bufano A, Dalmazio G, et al. Validation of American Thyroid Association Ultrasound Risk-Adapted Approach for Repeating Cytology in Benign Thyroid Nodules. Thyroid. 2020. PMID: 32718278. doi:10.1089/thy.2020.0351
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。